VCEL240920C50000
- 0.35
- 0.000.00%
Vericel Newsroom
Even Though Vericel (NASDAQ:VCEL) Has Lost US$267m Market Cap in Last 7 Days, Shareholders Are Still up 173% Over 5 Years
Vericel Corp Shares Are Trading Higher After TD Cowen Maintained a Buy Rating on the Stock and Raised Its Price Target From $55 to $60.
The Analyst Verdict: Vericel In The Eyes Of 7 Experts
Vericel Is Maintained at Buy by TD Cowen
Vericel Price Target Raised to $60.00/Share From $55.00 by TD Cowen
TD Cowen Maintains Buy on Vericel, Raises Price Target to $60
Express News | Vericel Corp : TD Cowen Raises Target Price to $60 From $55
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $57
CCORF analyst Caitlin Cronin maintains $Vericel(VCEL.US)$ with a buy rating, and maintains the target price at $57.According to TipRanks data, the analyst has a success rate of 62.5% and a total
BTIG Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $55
BTIG analyst Ryan Zimmerman maintains $Vericel(VCEL.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 48.7% and a total
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $60
TD Cowen analyst Josh Jennings maintains $Vericel(VCEL.US)$ with a buy rating, and adjusts the target price from $55 to $60.According to TipRanks data, the analyst has a success rate of 55.1% and a
Buy Rating on Vericel: Expanding Market Reach With FDA-Approved MACI Arthro Platform
Vericel Says US FDA Approves SBLA for Tissue Restoring Knee Repair Treatment - Shares Up Pre-Bell
Vericel Gains FDA Approval for Arthroscopic Delivery of MACI in Knee Cartilage Treatments
Express News | Vericel Announces FDA Approval and Commercial Availability of Maci Arthro
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
Express News | Vericel Corp Shares Down 1.4% After Co Files for Mixed Shelf Offering
Express News | Vericel Corp Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing
MediWound and Vericel Win FDA Paediatric Label Expansion for NexoBrid
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $55
TD Cowen analyst Josh Jennings maintains $Vericel(VCEL.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 51.2% and a total
TD Cowen Keeps Their Buy Rating on Vericel (VCEL)